country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-162462

Copy Link Print Information

Antitumor agent-151

Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC₅₀ = 0.79 μM) and antitumor activity in vitro (IC₅₀ = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3036751-77-3
Formel: C₂₂H₂₀FN₅O
Molecular Weight:389.43

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (265 KB)

Antitumor agent-151 Chemical Structure

CAS. Nr.: 3036751-77-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
Bone marrow cell	IC₅₀	>20 nM Compound: 7k	Cytotoxicity against normal bone marrow cell (unknown origin) assessed as cell proliferation incubated for 72 hrs by CCK-8 assay Cytotoxicity against normal bone marrow cell (unknown origin) assessed as cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]
HL-60	IC₅₀	40.5 nM Compound: 7k	Anti-leukemia activity against human HL-60 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay Anti-leukemia activity against human HL-60 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]
K562	IC₅₀	131.8 nM Compound: 7k	Anti-leukemia activity against human K562 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay Anti-leukemia activity against human K562 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]
Kasumi 1	IC₅₀	41.1 nM Compound: 7k	Anti-leukemia activity against human Kasumi 1 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay Anti-leukemia activity against human Kasumi 1 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]
MOLM-13	IC₅₀	30.1 nM Compound: 7k	Anti-leukemia activity against human MOLM-13 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay Anti-leukemia activity against human MOLM-13 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]
MV4-11	EC₅₀	0.078 μM Compound: 7k	Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 48 hrs by CCK-8 assay Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 48 hrs by CCK-8 assay	[PMID: 38620134]
MV4-11	EC₅₀	5.2 μM Compound: 7k	Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 24 hrs by CCK-8 assay Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 24 hrs by CCK-8 assay	[PMID: 38620134]
MV4-11	IC₅₀	0.03 μM Compound: 7k	Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]
OCI-AML2	IC₅₀	39.2 nM Compound: 7k	Anti-leukemia activity against human OCI-AML2 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay Anti-leukemia activity against human OCI-AML2 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]
THP-1	IC₅₀	79.7 nM Compound: 7k	Anti-leukemia activity against human THP-1 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay Anti-leukemia activity against human THP-1 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]
U-937	IC₅₀	78.2 nM Compound: 7k	Anti-leukemia activity against human U-937 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay Anti-leukemia activity against human U-937 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]

In Vitro

Antitumor agent-151 (7k) displays a strong activity for inhibition of other AML cell lines. The IC₅₀ values of Molm13, U937, OCI-AML2, THP-1, HL60, KASSUMI, and K562 cell lines are 30.1 ± 2.3, 78.2 ± 3.1, 39.2 ± 0.9, 79.7 ± 0.3, 40.5 ± 0.8, 41.1 ± 1.7, and 131.8 ± 1.5 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Antitumor agent-151 (7k, 10 mg/kg, ip, Female BALB/c nude mice bearing Mv4-11 AML cells) shows powerful antitumor efficacy^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 3036751-77-3
Molecular Weight 389.43
Formel C₂₂H₂₀FN₅O
SMILES

O=C(C1=C(CCN(C1)CC2=CC(C#N)=CC=C2)N3)N=C3NCC4=CC=C(C=C4)F
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (265 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Xinrong Xiang, et al. Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity. J Med Chem. 2024 Apr 25;67(8):6769-6792. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen